New Industries Require New Insight 

The microbiome and its role in human health represents a paradigm shift in how medicines will be developed. The PRI was founded to make Microbiotic Medicinal Products a therapeutic reality in Europe.

A Unique Collaborative Approach

The PRI, as a neutral and financially independent non-profit association, applies a unique collaborative approach to improve market access and provide technical and regulatory intelligence for its members.

The Future of Human Health

The PRI believes that the microbiome is the future of human medicine. Our members have a stake in regulatory, technical and collaboration efforts of the microbiome & human health space. 

Board Members 

President

Yakult Europe

Bruno Pot

Yakult Europe

Vice-President

Johnson-Johnson

Colette Shortt

Johnson-Johnson

Vice-President

Astel Medica

Nail Nasir

Astel Medica

Vice-President

YUN Probiotherapy

Ingmar Claes

YUN Probiotherapy

Treasurer

Biose

Stanislas Desjonquères

Biose

Secretary

Laurent Rios

VetAgro-Sup

Member

Luc Sterkman

Caelus Health

Member

Université d'Auvergne

Monique Alric

Université d’Auvergne

Luca Mogna

Probiotical

Member

Symbiopharm

Joachim Solfronk

Symbiopharm
IPSEN Pharma

Pascal Molimard

IPSEN Pharma

Charlotte Hemmingsen

Chr. Hansen

Board Members 

Tue Anker Mikkelsen

Ferring Pharmaceuticals
LNC Therapeutics

Sandrine Claus

LNC Therapeutics

Audrey Bru

Lallemand Health Solutions

Ana Enriquez

ADM Protexin

Frédérique Vieville

5QBD-Biotech

Member

Helene Cvejic

Accelsiors CRO

Massimo Marzorati

ProDigest

Benoît Fouchaq

Biofortis Mérieux NutriSciences

Member

POSTECH

Sin-Hyeog Im

POSTECH

Our Team

Magali

Scientific & Regulatory Affairs Director

Joseph

Business Development & Member Services Manager
Alice

Alice

Regulatory Affairs Associate 

Nick

Pharmabiotics Event Director

Our Members

Start Ups

Start Ups

Biotechs

Biotechs

Investors

Investors

CROs

Research Institutions

LBP Developers

LBP Developers

CDMOs

CDMOs

Pharma

Membership in the PRI plays an important role in several of our members’ development & marketing strategies. 

Intelligence

Development Planning

Networking

Scientific Foresight

Investment

What are Microbiotic Medicinal Products (MMPs)?

The PRI defines MMPs as any medicinal product containing living, dead or fragments…, of components of the microbiome (i.e. bacteria, yeasts, phages, etc…) with the purpose to prevent or treat human diseases through a pharmacological, microbiological, neurological, immunological or metabolic mode of action, or make a medical diagnosis.

Non-Living Cells

Non-Living Cells

Live Biotherapeutic Products

Live Biotherapeutic Products

Faeces-derived Rx

Faeces-derived Rx

Phage Therapy

Phage Therapy

The PRI is a non-profit, Pro-industry group, dedicated to bringing Microbiotic Medicinal Products to market in Europe.

Expertise

Patients/Health

Medicine

Synergy

Find out more about the PRI from some of her members…

One-to-One Partnering

Microbiome dedicated one-to-one partnering forum. Schedule 20+ meetings with decision makers from Academia & Industry.

Conference

30+ presentations covering topics such as Cancer, Gut-Lung Axis, Urogenital as well as Regulatory Affairs and Market Trends.

Exhibition

Tailor suited solutions for your business needs. Promote your products and services to the Global Microbiome Community.

Innovation Showcase

Start-ups, spin-offs, academics & entrepreneurs present the latest innovations of microbiome products, services and research.

Contact Us

Our team is available to answer any questions you may have. Please contact us by phone or email us directly. 

Send us a message: